[1]邹小白 郑旭琴.蛋白质组学在甲状腺疾病中的研究进展[J].国际内分泌代谢杂志,2018,38(03):158-162.[doi:10.3760/cma.j.issn.1673-4157.2018.03.004]
　Zou Xiaobai,Zheng Xuqin..The progress of proteomics in thyroid diseases[J].International Journal of Endocrinology and Metabolism,2018,38(03):158-162.[doi:10.3760/cma.j.issn.1673-4157.2018.03.004]
点击复制

蛋白质组学在甲状腺疾病中的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年03期
页码:
158-162
栏目:
综述
出版日期:
2018-05-20

文章信息/Info

Title:
The progress of proteomics in thyroid diseases
作者:
邹小白 郑旭琴
210029 南京医科大学第一附属医院内分泌科
Author(s):
Zou Xiaobai;  Zheng Xuqin.
Department of Endocrinology & Metabolism, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
关键词:
蛋白质组学;  甲状腺疾病;  分子标志物
Keywords:
Proteomics;  Thyroid diseases;  Molecular markers
DOI:
10.3760/cma.j.issn.1673-4157.2018.03.004
摘要:
蛋白质组学是在蛋白质的整体水平上进行研究,从而获得关于细胞代谢、疾病发展等过程的全面认识。近几年来,蛋白质组学中差异蛋白质的研究在判断甲状腺结节的良、恶性及了解各种甲状腺疾病的发病机制中发挥日趋重要的作用。研究表明,一些差异蛋白表达的上调可以抑制细胞凋亡及上调细胞凋亡阈值,致使细胞异常增殖及分化,最终导致肿瘤; 也可促进自身免疫炎性反应,加重Graves病或桥本甲状腺炎的病情。
Abstract:
Proteomics mainly refers to obtain the comprehensive understanding of the process of cell metabolism and disease development through the research at the overall level of protein. Recently, the differential expression of proteins in proteomics plays an increasingly crucial role in distinguishing benign from malignant thyroid nodules and understanding the pathogenesis of various thyroid diseases. Many studies reveal that the up-regulation of some differentially expressed proteins can inhibit apoptosis and up-regulate the threshold of apoptosis, resulting in abnormal proliferation and differentiation of cells, eventually leading to the development of tumors. Also, such up-regulation can promote autoimmune inflammation, aggravating Graves' disease or Hashimoto's thyroiditis.

参考文献/References:


[1] Mosele N,Smith A,Galli M,et al.MALDI-MSI analysis of cytological smears: the study of thyroid cancer[J].Methods Mol Biol, 2017,1618:37-47.DOI:10.1007/978-1-4939-7051-3_5.
[2] Pagni F,Mainini V,Garancini M,et al. Proteomics for the diagnosis of thyroid lesions: preliminary report[J].Cytopathology,2015,26(5):318-324. DOI:10.1111/cyt.12166.
[3] Melo M, Gaspar da Rocha A, Batista R,et al. TERT, BRAF, and NRAS in primary thyroid cancer and metastatic disease[J].J Clin Endocrinol Metab,2017,102(6):1898-1907. DOI:10.1210/jc.2016-2785.
[4] Cafarelli TM,Desbuleux A,Wang Y,et al. Mapping, modeling, and characterization of protein-protein interactions on a proteomic scale[J].Curr Opin Struct Biol,2017,44:201-210.DOI:10.1016/j.sbi.2017.05.003.
[5] 郭春燕,詹克慧.蛋白质组学技术研究进展及应用[J].云南农业大学学报,2010,25(4):583-591.DOI:10.3969/j.issn.1004-390X.2010.04.024.
[6] 王英超,党源,李晓艳,等.蛋白质组学及其技术发展[J].生物技术通讯,2010,21(1):139-144.DOI:10.3969/j.issn.1009-0002.2010.01.034.
[7] Giusti L,Iacconi P,Ciregia F,et al. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers[J].J Proteome Res,2008,7(9):4079-4088.DOI:10.1021/pr8000404.
[8] Ciregia F,Giusti L,Molinaro A,et al. Presence in the pre-surgical fine-needle aspiration of potential thyroid biomarkers previously identified in the post-surgical one[J].PLoS One,2013,8(9):e72911.DOI:10.1371/journal.pone.0072911.
[9] 张立勇,赵晓航,吴旻.膜联蛋白Ⅰ的结构和功能[J].生物化学与生物物理进展,2002,29(4):514-517.DOI:10.3321/j.issn:1000-3282.2002.04.004.
[10] Petrella A, Festa M,Ercolino SF,et al. Induction of annexin-1 during TRAIL-induced apoptosis in thyroid carcinoma cells[J].Cell Death Differ,2005,12(10):1358-1360. DOI:10.1038/sj.cdd.4401645.
[11] Musso R, Di Cara G, Albanese NN,et al. Differential proteomic and phenotypic behaviour of papillary and anaplastic thyroid cell lines[J].J Proteomics,2013,90:115-125.DOI:10.1016/j.jprot.2013.01.023.
[12] Villar-Taibo R,Peteiro-González D,Cabezas-Agrícola JM,et al.Aggressiveness of the tall cell variant of papillary thyroid carcinoma is independent of the tumor size and patient age[J]. Oncol Lett,2017,13(5):3501-3507.DOI:10.3892/ol.2017.5948.
[13] Liu C,Chen T, Liu Z. Associations between BRAF(V600E)and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis[J].World J Surg Oncol,2016,14(1):241.DOI:10.1186/s12957-016-0979-1.
[14] Park WS,Chung KW,Young MS,et al.Differential protein expression of lymph node metastases of papillary thyroid carcinoma harboring the BRAF mutation[J].Anticancer Res,2013,33(10):4357-4364.
[15] Shan YX,Liu TJ,Su HF,et al.Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells[J].J Mol Cell Cardiol,2003,35(9):1135-1143.
[16] Seidler DG,Goldoni S,Agnew C,et al. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation[J].J Biol Chem,2006,281(36):26408-26418.DOI:10.1074/jbc.M602853200.
[17] Buraschi S,Neill T,Goyal A,et al. Decorin causes autophagy in endothelial cells via Peg3[J].Proc Natl Acad Sci U S A,2013,110(28):E2582-E2591.DOI:10.1073/pnas.1305732110.
[18] Martínez-Aguilar J,Clifton-Bligh R, Molloy MP. Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy[J].Sci Rep,2016,6:23660.DOI:10.1038/srep23660.
[19] Meng S,Zhang W,Guan LJ,et al. Proteomic analysis reveals aberrant expression of CALR and HSPA5 in thyroid tissues of Graves' disease[J].Clin Biochem,2017,50(1-2):40-45. DOI:10.1016/j.clinbiochem.2016.08.014.
[20] Barrio-Barrio J,Sabater AL,Bonet-Farriol E,et al. Graves' ophthalmopathy: VISA versus EUGOGO classification, assessment, and management[J].J Ophthalmol,2015,2015:249125. DOI:10.1155/2015/249125.
[21] Bartalena L,Baldeschi L,Boboridis K,et al. The 2016 European thyroid association/European group on Graves' orbitopathy guidelines for the management of Graves' orbitopathy[J].Eur Thyroid J,2016,5(1):9-26.DOI:10.1159/000443828.
[22] Matheis N,Okrojek R,Grus FH,et al.Proteomics of tear fluid in thyroid-associated orbitopathy[J].Thyroid,2012,22(10):1039-1045. DOI:10.1089/thy.2012.0119.
[23] Aass C,Norheim I,Eriksen EF,et al.Comparative proteomic analysis of tear fluid in Graves' disease with and without orbitopathy[J].Clin Endocrinol(Oxf),2016,85(5):805-812.DOI:10.1111/cen.13122.
[24] Aass C,Norheim I,Eriksen EF,et al.Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy[J].PLoS One,2017,12(4):e0175274.DOI:10.1371/journal.pone.0175274.
[25] Matheis N,Lantz M,Grus FH,et al.Proteomics of orbital tissue in thyroid-associated orbitopathy[J].J Clin Endocrinol Metab,2015,100(12):E1523-E1530.DOI:10.1210/jc.2015-2976.
[26] Fiore E,Rago T,Latrofa F,et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine[J].Endocr Relat Cancer,2011,18(4):429-437. DOI:10.1530/ERC-11-002.
[27] Chen YK,Lin CL,Cheng FT,et al.Cancer risk in patients with Hashimoto's thyroiditis: a nationwide cohort study[J].Br J Cancer,2013,109(9):2496-2501.DOI:10.1038/bjc.2013.597.
[28] Pagni F,De Sio G,Garancini M,et al.Proteomics in thyroid cytopathology: relevance of MALDI-imaging in distinguishing malignant from benign lesions[J].Proteomics,2016,16(11-12):1775-1784.DOI:10.1002/pmic.201500448.

相似文献/References:

[1]杨叶虹,胡仁明.SELDI-TOF-MS技术及其在糖尿病研究中的应用[J].国际内分泌代谢杂志,2007,(04):261.
[2]周鹏 张少红 韦晓 陈国芳 刘超.季节性变化对甲状腺激素的影响[J].国际内分泌代谢杂志,2019,39(05):349.[doi:10.3760/cma.j.issn.1673-4157.2019.05.015]
　Zhou Peng,Zhang Shaohong,Wei Xiao,et al.Effects of seasonal changes on thyroid hormones[J].International Journal of Endocrinology and Metabolism,2019,39(03):349.[doi:10.3760/cma.j.issn.1673-4157.2019.05.015]

备注/Memo

备注/Memo:

通信作者:郑旭琴,Email: zhengxuqin@njmu.edu.cn
更新日期/Last Update: 2018-03-30